Last reviewed 2026-04-23 · How we verify

Unique Pharmaceutical Laboratories, India

Unique Pharmaceutical Laboratories' drug is a small molecule in phase 3 clinical trials.

Unique Pharmaceutical Laboratories' drug is a small molecule in phase 3 clinical trials. Used for Phase 3 clinical trials for an unspecified indication.

At a glance

Mechanism of action

Unfortunately, there is limited information available on the exact mechanism of action of this drug.

Approved indications

• Phase 3 clinical trials for an unspecified indication

Common side effects

• Unknown

Key clinical trials

• A Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) With Clotrimazole Troche 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis. (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Unique Pharmaceutical Laboratories, India CI brief — competitive landscape report
• Unique Pharmaceutical Laboratories, India updates RSS · CI watch RSS
• Thinq Pharma-CRO Pte. Ltd. portfolio CI